PA8584901A1 - Derivados sustituidos de 1,4-di-piperidin-4-il-piperazina y su uso como antagonistas de neuroquininas - Google Patents
Derivados sustituidos de 1,4-di-piperidin-4-il-piperazina y su uso como antagonistas de neuroquininasInfo
- Publication number
- PA8584901A1 PA8584901A1 PA20038584901A PA8584901A PA8584901A1 PA 8584901 A1 PA8584901 A1 PA 8584901A1 PA 20038584901 A PA20038584901 A PA 20038584901A PA 8584901 A PA8584901 A PA 8584901A PA 8584901 A1 PA8584901 A1 PA 8584901A1
- Authority
- PA
- Panama
- Prior art keywords
- disorders
- neuroquinins
- same
- piperazina
- piperidin
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 9
- 208000035475 disorder Diseases 0.000 abstract 9
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- 206010047700 Vomiting Diseases 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 230000000903 blocking effect Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 208000027932 Collagen disease Diseases 0.000 abstract 1
- 206010012335 Dependence Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 208000025747 Rheumatic disease Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000022821 personality disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000002455 vasospastic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
LA INVENCION SE REFIERE A DERIVADOS SUSTITUIDOS DE 1,4-DI-PIPERIDIN-4-IL- PIPERAZINA QUE TIENEN ACTIVIDAD ANTAGONISTA DE LAS NEUROQUININAS, EN PARTICULAR ACTIVIDAD ANTAGONISTA DE NK1, SU PREPARACION, COMPOSICIONES QUE LOS COMPRENDEN Y SU USO COMO MEDICAMENTO, EN PARTICULAR PARA EL TRATAMIENTO DE LA EMESIS, ANSIEDAD, DEPRESION, PANCREATITIS Y SCI. LOS COMPUESTOS DE ACUERDO CON LA INVENCION SE PUEDEN REPRESENTAR MEDIANTE LA FORMULA GENERAL (1). Y COMPRENDEN TAMBIEN LAS SALES DE ADICION CON ACIDOS O BASES ACEPTABLES PARA USO FARMACEUTICO DE LOS MISMOS, LAS FORMAS ESTEREOQUIMICAMENTE ISOMERICAS DE LOS MISMOS, LA FORMA DE N-OXIDO DE LOS MISMOS Y PROFARMACOS DE LOS MISMOS, EN DONDE TODOS LOS SUSTITUYENTES SE DEFINEN COMO EN LA REIVINDICACION 1. EN VISTA DE SU CAPACIDAD PARA ANTAGONIZAR LAS ACCIONES DE LAS NEUROQUININAS POR BLOQUEO DE LOS RECEPTORES DE NEUROQUININAS, Y EN PARTICULAR ANTAGONIZAR LAS ACCIONES DE LA SUSTANCIA P POR BLOQUEO DEL RECEPTOR NK1, LOS COMPUESTOS DE ACUERDO CON LA INVENCION SON UTILES COMO MEDICAMENTOS, EN PARTICULAR EN EL TRATAMIENTO PROFILACTICO Y TERAPEUTICO DE CONDICIONES MEDIADAS POR NEUROQUININAS, TALES COMO, POR EJEMPLO, TRASTORNOS DEL SNC, EN PARTICULAR DE LA DEPRESION, TRASTORNOS DE ANSIEDAD, TRASTORNOS RELACIONADOS CON EL ESTRES, TRASTORNOS DEL SUEÑO, TRASTORNOS COGNITIVOS, TRASTORNOS DE LA PERSONALIDAD, TRASTORNOS ESQUIZOAFECTIVOS, TRASTORNOS DE LA ALIMENTACION, TRASTORNOS NEURODEGENERATIVOS, TRASTORNOS DE ADICCION, TRASTORNOS DEL ANIMO, DISFUNCION SEXUAL, DOLOR Y OTRAS CONDICIONES RELACIONADAS CON EL SNC; INFLAMACION, TRASTORNOS ALERGICOS; EMESIS, TRASTORNOS GASTROINTESTINALES, EN PARTICULAR EL SINDROME DE COLON IRRITABLE (SCI); TRASTORNOS DE LA PIEL; TRASTORNOS VASOESPASTICOS; ENFERMEDADES FIBROSANTES Y DEL COLAGENO; TRASTORNOS RELACIONADOS CON EL INCREMENTO O LA SUPRESION INMUNE Y ENFERMEDADES REUMATICAS Y CONTROL DEL PESO CORPORAL.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP0211328 | 2002-10-08 | ||
PCT/EP2002/014836 WO2004056772A1 (en) | 2002-12-23 | 2002-12-23 | Substituted 1,4-di-piperidin-4-yl-piperazine derivatives and their use as tachykinin antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8584901A1 true PA8584901A1 (es) | 2005-10-28 |
Family
ID=32094938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20038584901A PA8584901A1 (es) | 2002-10-08 | 2003-10-08 | Derivados sustituidos de 1,4-di-piperidin-4-il-piperazina y su uso como antagonistas de neuroquininas |
Country Status (19)
Country | Link |
---|---|
US (1) | US7410970B2 (es) |
EP (1) | EP1551804B1 (es) |
JP (1) | JP4674086B2 (es) |
KR (1) | KR101049074B1 (es) |
AR (1) | AR041545A1 (es) |
AT (1) | ATE418543T1 (es) |
AU (1) | AU2003282115B2 (es) |
BR (1) | BR0315098A (es) |
CA (1) | CA2499903C (es) |
DE (1) | DE60325493D1 (es) |
EA (1) | EA009217B1 (es) |
ES (1) | ES2319642T3 (es) |
HK (1) | HK1084394A1 (es) |
HR (1) | HRP20050309A2 (es) |
IL (1) | IL167885A (es) |
MY (1) | MY141736A (es) |
PA (1) | PA8584901A1 (es) |
TW (1) | TWI324995B (es) |
WO (1) | WO2004033428A1 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9923748D0 (en) | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
USRE39921E1 (en) | 1999-10-07 | 2007-11-13 | Smithkline Beecham Corporation | Chemical compounds |
GB0025354D0 (en) | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
GB0203020D0 (en) | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
JP2005522436A (ja) | 2002-02-08 | 2005-07-28 | グラクソ グループ リミテッド | ピペリジルカルボキシアミド誘導体またはそのタキキニン介在疾患の治療における使用 |
GB0203022D0 (en) | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
JO2485B1 (en) * | 2002-12-23 | 2009-01-20 | شركة جانسين فارماسوتيكا ان. في | 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists |
JO2696B1 (en) | 2002-12-23 | 2013-03-03 | شركة جانسين فارماسوتيكا ان. في | Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists |
CN1822828A (zh) | 2003-06-10 | 2006-08-23 | 詹森药业有限公司 | 用于以阿片类药物为基础治疗疼痛的含取代的1,4-二哌啶-4-基哌嗪衍生物的新颖制剂 |
BRPI0509803A (pt) | 2004-04-13 | 2007-09-18 | Incyte Corp | derivados de piperazinilpiperidina como antagonistas de receptor de quimiocina |
WO2005123081A2 (en) * | 2004-06-22 | 2005-12-29 | Janssen Pharmaceutica N.V. | (2-benzyl-4-{4-[1-(tetrahydrofuran-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-trifluoromethyl-phenyl))-methanone for the treatment of schizophrenia |
WO2006071958A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
WO2006071875A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
AU2006222061B2 (en) * | 2005-03-03 | 2011-04-28 | Janssen Pharmaceutica N.V. | Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists |
BRPI0608847A2 (pt) * | 2005-03-08 | 2010-02-02 | Janssen Pharmaceutica Nv | derivados de diaza-espiro-[4,4]-nonano substituìdos e seu uso como antagonistas de neurocinina |
US7592344B2 (en) * | 2005-11-30 | 2009-09-22 | Solvay Pharmaceuticals Gmbh | NK1 and NK2-antagonists and compositions and methods of using the same |
CA2646958A1 (en) * | 2006-03-21 | 2007-09-27 | Schering Corporation | Heterocyclic substituted pyridine compounds with cxcr3 antagonist activity |
US20090209541A1 (en) * | 2006-06-16 | 2009-08-20 | Dr. Reddy's Laboratories Ltd. | Aprepitant compositions |
EP2041117B1 (en) * | 2006-07-14 | 2012-08-22 | Merck Sharp & Dohme Corp. | Heterocyclic substituted piperazine compounds with cxcr3 antagonist activity |
EP2473038A4 (en) * | 2009-09-04 | 2013-10-23 | United Paragon Associates Inc | COMPOSITIONS FOR TREATING SUFFICIENT OR ILLNESSES PROVIDED BY NEUROKININ-2-RECEPTOR ACTIVITY |
EP2953934B1 (en) | 2013-02-08 | 2018-04-11 | General Mills, Inc. | Reduced sodium food products |
KR101472916B1 (ko) | 2013-06-27 | 2014-12-16 | 한국과학기술연구원 | 모르폴린 또는 피페라진 화합물, 및 도네페질을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물 |
WO2015200594A2 (en) | 2014-06-25 | 2015-12-30 | Emory University | Methods of managing conditioned fear with neurokinin receptor antagonists |
RU2617694C1 (ru) * | 2015-12-24 | 2017-04-26 | Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) | Амиды акриловой и метакриловой кислот с олигопиперидинами и способ их получения |
US11458129B2 (en) | 2017-11-02 | 2022-10-04 | California Institute Of Technology | Neurokinin antagonists and uses thereof |
US20200206144A1 (en) * | 2019-01-02 | 2020-07-02 | Lauren Lukas VanderSpek | Targeted Nanoparticles for Glioblastoma Theranostics |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2676055B1 (fr) * | 1991-05-03 | 1993-09-03 | Sanofi Elf | Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
NZ321575A (en) * | 1995-10-30 | 1999-05-28 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives |
HU224225B1 (hu) * | 1995-12-01 | 2005-06-28 | Sankyo Co. Ltd. | Tachikinin receptor antagonista hatású heterociklusos vegyületek, ezek előállítási eljárása és alkalmazásuk gyógyszerkészítmények előállítására |
JO2485B1 (en) * | 2002-12-23 | 2009-01-20 | شركة جانسين فارماسوتيكا ان. في | 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists |
US7323415B2 (en) * | 2004-04-23 | 2008-01-29 | Jsr Corporation | Polishing pad for semiconductor wafer, polishing multilayered body for semiconductor wafer having same, and method for polishing semiconductor wafer |
-
2003
- 2003-10-06 MY MYPI20033797A patent/MY141736A/en unknown
- 2003-10-07 BR BR0315098-4A patent/BR0315098A/pt not_active IP Right Cessation
- 2003-10-07 ES ES03773731T patent/ES2319642T3/es not_active Expired - Lifetime
- 2003-10-07 WO PCT/EP2003/050697 patent/WO2004033428A1/en active Application Filing
- 2003-10-07 AT AT03773731T patent/ATE418543T1/de not_active IP Right Cessation
- 2003-10-07 TW TW092127724A patent/TWI324995B/zh active
- 2003-10-07 EP EP03773731A patent/EP1551804B1/en not_active Expired - Lifetime
- 2003-10-07 AU AU2003282115A patent/AU2003282115B2/en not_active Ceased
- 2003-10-07 DE DE60325493T patent/DE60325493D1/de not_active Expired - Lifetime
- 2003-10-07 EA EA200500616A patent/EA009217B1/ru not_active IP Right Cessation
- 2003-10-07 US US10/527,821 patent/US7410970B2/en not_active Expired - Fee Related
- 2003-10-07 CA CA2499903A patent/CA2499903C/en not_active Expired - Fee Related
- 2003-10-07 AR ARP030103649A patent/AR041545A1/es unknown
- 2003-10-07 KR KR1020057003472A patent/KR101049074B1/ko not_active IP Right Cessation
- 2003-10-07 JP JP2004542503A patent/JP4674086B2/ja not_active Expired - Fee Related
- 2003-10-08 PA PA20038584901A patent/PA8584901A1/es unknown
-
2005
- 2005-04-04 HR HR20050309A patent/HRP20050309A2/xx not_active Application Discontinuation
- 2005-04-06 IL IL167885A patent/IL167885A/en not_active IP Right Cessation
-
2006
- 2006-04-19 HK HK06104676.7A patent/HK1084394A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HRP20050309A2 (en) | 2006-07-31 |
ATE418543T1 (de) | 2009-01-15 |
CA2499903A1 (en) | 2004-04-22 |
EA009217B1 (ru) | 2007-12-28 |
TW200413319A (en) | 2004-08-01 |
BR0315098A (pt) | 2005-08-16 |
DE60325493D1 (de) | 2009-02-05 |
CA2499903C (en) | 2011-06-14 |
TWI324995B (en) | 2010-05-21 |
MY141736A (en) | 2010-06-15 |
AU2003282115B2 (en) | 2009-10-01 |
KR101049074B1 (ko) | 2011-07-15 |
AR041545A1 (es) | 2005-05-18 |
US7410970B2 (en) | 2008-08-12 |
AU2003282115A1 (en) | 2004-05-04 |
JP4674086B2 (ja) | 2011-04-20 |
US20060167008A1 (en) | 2006-07-27 |
EP1551804A1 (en) | 2005-07-13 |
WO2004033428A1 (en) | 2004-04-22 |
JP2006510602A (ja) | 2006-03-30 |
HK1084394A1 (en) | 2006-07-28 |
EP1551804B1 (en) | 2008-12-24 |
KR20050059164A (ko) | 2005-06-17 |
IL167885A (en) | 2010-04-29 |
EA200500616A1 (ru) | 2005-10-27 |
ES2319642T3 (es) | 2009-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8584901A1 (es) | Derivados sustituidos de 1,4-di-piperidin-4-il-piperazina y su uso como antagonistas de neuroquininas | |
PA8593301A1 (es) | Derivados de 1-piperidin-4-il-4-pirrolidin-3-il-piperazina sustituidos y su uso como antagonistas de neuroquininas | |
EA202191498A1 (ru) | 9-замещенные производные аминотриазолохиназолина в качестве антагонистов аденозиновых рецепторов, фармацевтические композиции и их применение | |
DOP2009000231A (es) | Derivados de carboxamida imidazolidina como moduladores de p2x7 | |
CL2020001762A1 (es) | Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464) | |
PH12020550341A1 (en) | Niraparib formulations | |
MX2016014634A (es) | Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. | |
CR20220105A (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
CY1108932T1 (el) | Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων | |
MX2020014156A (es) | Oxadiazoles como agonistas de los receptores muscarinicos m1 y/o m4. | |
ATE388708T1 (de) | Piperazinderivate und anwendungsverfahren | |
PA8657301A1 (es) | Derivados sustituidos de triazolona, tetrazolona e imidazolona para uso como medicamento | |
EA201892153A1 (ru) | Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf | |
MX2020010568A (es) | Derivados de urea ciclica fusionada como antagonista de crhr2. | |
MX2021006012A (es) | Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso. | |
CO2023011781A2 (es) | Formas de dosificación farmacéuticas que comprenden (4s)–24–cloro–4–etil–73–fluoro–35–metoxi–32,5–dioxo–14–(trifluorometil)–32h–6–aza–3(4,1)–piridina–1(1)–[1,2,3]triazola–2(1,2),7(1)–dibencenaheptafano–74–carboxamida | |
HRP20050554B1 (hr) | Supstituirani 1- piperidin-3-il-4-piperidin-4-il-piperazinski derivati i njihova primjena kao neurokininskih antagonista | |
BR112019024804A2 (pt) | compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas | |
EA202092763A1 (ru) | Применение бисамидного производного малоновой кислоты для лечения аллергических и других заболеваний человека и животных | |
EA201892142A1 (ru) | Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf | |
MX2021009082A (es) | Compuestos quimicos. | |
MX2018013969A (es) | Combinacion de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda. | |
MX2021000966A (es) | Piridopirimidinas como inhibidores del receptor de histamina h4. | |
AR019322A1 (es) | Derivados de sulfonilo sustituido por heterociclo-etanodionanilina sustituida por heterociclo, composicion farmaceutica que los contiene y su uso para lamanufactura de un medicamento | |
EA202092013A1 (ru) | Пиридинкарбонильные производные и их терапевтические применения в качестве ингибиторов trpc6 |